% | $
Quotes you view appear here for quick access.

Infinity Pharmaceuticals, Inc. (INFI) Message Board

  • enrjrr enrjrr May 16, 2013 3:15 PM Flag


    Lots of misinformation today. Yes, GS1101 is active in CLL and MCL. Yes, IPI-145 is also active. Both of these drugs target PI3K. Gilead is likely 2 years ahead of Infinity in their development. That said, all of these things were well know before the publication of abstracts yesterday. As such, Eyeview today's selling as a classic overreaction. More over, the data for infinity's product is a phase 1, dose escalation trial. Response rates may improve as more patients are dosed at the appropriate dose. It is much too early to draw conclusions between these two agents. Those that sell today may regret it

1.32+0.02(+1.54%)Jun 24 4:00 PMEDT